[Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) in the field of obstetrics and gynecology].
BRL 25000, consisting of 250 mg amoxicillin (AMPC) and 125 mg clavulanic acid (CVA), was studied in the field of obstetrics and gynecology. Tissue concentrations The concentrations in venous serum and arterial serum of uterus, different sites uterus, oviduct and ovarium were determined. Tissue concentrations of AMPC and CVA corresponded to 45--75% and 20--50%, respectively of serum concentrations. The good responses were obtained in cases with intrapelvic infection and the overall clinical effective responses were obtained in 100% of patients. Effectiveness was found microbiologically and clinically in infections due to AMPC resistant organisms. No side effects were found.
D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000378:metabolism* / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000378:metabolism*; D001424:Bacterial Infections / Q000188:drug therapy*; D002969:Clavulanic Acids / Q000378:metabolism* / Q000627:therapeutic use; D004338:Drug Combinations / Q000378:metabolism / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D004338:Drug Combinations; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin